Source: NICE
Area: Evidence > Guidelines
The National Institute for Health and Clinical Excellence has issued guidance on the use of dexamethasone intravitreal implants for the treatment of macular oedema caused by retinal vein occlusion (RVO).
The following recommendations have been made (taken directly from source):
. Dexamethasone intravitreal implant is recommended as an option for the treatment of macular oedema following central retinal vein occlusion.
. Dexamethasone intravitreal implant is recommended as an option for the treatment of macular oedema following branch retinal vein occlusion when:
- treatment with laser photocoagulation has not been beneficial, or
- treatment with laser photocoagulation is not considered suitable because of the extent of macular haemorrhage.
. People currently receiving dexamethasone intravitreal implant for the treatment of macular oedema secondary to branch retinal vein occlusion who do not meet the criteria ...
Uncategorized